Could a simple artery shot replace opioids for Post-Brain bleed headaches?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged ≥18 years with confirmed SAH via computed tomography or magnetic resonance imaging 2. Undergoing DSA as part of routine diagnostic or therapeutic care 3. Experiencing headaches with baseline severity assessable using Headache Impact Test (HIT-6) questionnaire and 11-point Numeric Rating Scale (NRS) 4. Conscious patients who can understand and sign informed consent form 5. Hemodynamically stable and suitable for intra-arterial procedures 5\) Willingness to comply with study procedures and follow-ups Exclusion Criteria: 1. Known allergy or hypersensitivity to lidocaine or amide-type anesthetics 2. Known allergy or hypersensitivity to Intralipid® (intravenous fat emulsion) or any of its components, including egg phospholipids or soy-based products 3. Known allergy or hypersensitivity to methylprednisolone, corticosteroids, any component of the Solu-Medrol® formulation 4. Diagnostic abnormalities at baseline, including ECG abnormalities (e.g., prolonged PR/QTc intervals, heart block, arrhythmias) 5. Cardiac conditions including history of heart block, Stokes-Adams syndrome, Wolff-Parkinson-White syndrome, or use of antiarrhythmics 6. Steroid-induced psychiatric history; uncontrolled seizures; uncontrolled diabetes; glaucoma/ocular hypertension; current/recent high-dose systemic steroids. 7. Previous IA lidocaine or methylprednisolone (or similar) therapy prior to enrollment 8. Alternative headache etiology (e.g., migraines, tension-type headache) 9. Unable to report pain reliably due to severe cognitive or communication deficits 10. Severe hemodynamic instability precluding safe DSA participation 11. Contraindications to IA catheterization or DSA (e.g., severe peripheral vascular disease, contrast allergies) 12. Severe renal impairment (eGFR \<30 mL/min/1.73 m²) 13. Severe hepatic impairment (e.g., Child-Pugh Class C) 14. Active systemic infections 15. Severe comorbid conditions with life expectancy \<30 days 16. Participants who are pregnant or breastfeeding 17. Conditions or concomitant medications listed in the USPI for study drugs that would compromise safety or data quality 18. Current participation in another clinical trial